A compilation of research working groups on drug utilisation across Europe

BMC Research Notes

Luisa Ibáñez¹  Joan-Ramon Laporte¹  Joan Fortuny²  Marietta Rottenkolber⁵  Marieke Wilma Schoonen⁴  Joerg Hasford⁵  Hans Petri⁶  Pili Ferrer³  Elena Ballarín¹  Juan Fernando Pacheco¹  Mònica Sabaté¹ 

[1] Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Pg. Vall d’Hebron 119-129, Barcelona 08035, Spain;Global Clinical Epidemiology Department, Novartis Pharma AG, Gran Vía Corts Catalanes, 764, 08013 Barcelona, Spain;Fundació Institut Català de Farmacologia, Pg. Valld’Hebron 119-129, Barcelona 08035, Spain;Center for Observational Research, Amgen, ltd., 1, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UK;Institute for Medical Information Sciences, Biometry and Epidemiology Ludwig Maximillians Universität-München, Marchioninistr. 15, 81377 Munich, Germany;Hoffmann- La Roche, 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TWLondon, UK

关键词: Review;    National databases;    Drug consumption;    Drug utilisation;    European network;    Pharmacovigilance;    Pharmacoepidemiology;   

Others  :  1134283
DOI  :  10.1186/1756-0500-7-143

 received in 2013-09-30, accepted in 2014-03-01,  发布年份 2014

【 摘 要 】

Background

The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published.

As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups.

Findings

Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.

Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE’S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented.

Conclusions

We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health.

【 授权许可】

   
2014 Sabaté et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]WHO: The selection and use of essential medicines (Report of the WHO Expert Committee, 2005 WHO Technical Report Series 2006;933).
• [2]Hartzema AG, Tilson HH, Chan KH: Pharmacoepidemiology and therapeutic risk management. 1st edition. Cincinatti: Harvey Whitney Books; 2008.
• [3]PROTECT Projecthttp://www.imi-protect.eu/ webcite. Accessed September/27, 2013
• [4]Dukes Me: Drug utilization studies. Methods and uses. Finland: WHO Regional Publications; 1993. European Series, Nº45
• [5]Platt R, Madre L, Reynolds R, Tilson H: Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008, 17:1175-1182.
• [6]Tannen RL, Weiner MG, Xie D: Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009, 27:338-b81.
• [7]Abbing-Karahagopian V, Kurz X, de Vries F, van Staa TP, Alvarez Y, Hesse U, Hasford J, Van Dijk L, De Abajo FJ, Weil JG, Grimaldi-Bensouda L, Egberts AC, Reynolds RF, Klungel OH: Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the protect project. Curr Clin Pharmacol Curr Clin Pharmacol 2013. [Epub ahead of print]
• [8]Walley T, Folino-Gallo P, Barry M, Bruzzone M, DeJoncheere K, Rosian I, Schröder H, Tilson L, Vogler S, on behalf of the EuroMedStat Group: The EuroMedStat proposals on indicators for price and utilization. Italian Journal of Public Health 2006, 3:15-21.
• [9]CNC Drug Utilization Results http://www.pharmacoepi.org/eurodurg/workgr/ webcite Accessed September/17, 2013
• [10]Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H, ESAC Project Group: European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004, 58:419-428.
• [11]Laslett LJ, Alagona P Jr, Clark BA 3rd, Drozda JP Jr, Saldivar F, Wilson SR, Poe C, Hart M: The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012, 25(25 Suppl):S1-49.
• [12]Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T: Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-86.
• [13]Blake KV, Prilla S, Accadebled S, Guimier M, Biscaro M, Persson I, Arlett P, Blackburn S, Fitt H: European medicines agency review of post-authorisation studies with implications for the European network of centres for pharmacoepidemiology and pharmacovigilance. Pharmacoepidemiol Drug Saf 2011, 20:1021-1029.
• [14]Almansa J, Vermunt JK, Forero CG, Vilagut G, De Graaf R, De Girolamo G, Alonso J: Measurement and description of underlying dimensions of comorbid mental disorders using factor mixture models: results of the ESEMeD project. Int J Methods Psychiatr Res 2011, 20:116-33.
• [15]Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I: Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol 2013, 20:686-91.